Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066698 · ClinicalTrials.gov registry record · Phase 2
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05066698 is a Phase 2 study that was terminated before completion, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 8 participants.
The verdict
NCT05066698, a Phase 2 study, was terminated before completion, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
Interventions
- BIOLOGICAL ST266
- OTHER 0.67% Sodium Chloride Ophthalmic Solution
- BIOLOGICAL Open-label ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066698
The ClinicalTrials.gov registry entry for NCT05066698 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ST266 is the first listed.
NCT05066698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066698 about?
NCT05066698 is a clinical study titled "ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects". The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months po...
What is the current status of trial NCT05066698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-04-27. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT05066698?
The interventions under investigation include: ST266 (BIOLOGICAL), 0.67% Sodium Chloride Ophthalmic Solution (OTHER), Open-label ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05066698?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.